OMIDRIA Special Ep. 4 From Trial to OMIDRIA on board for Every Surgery: Experts Share Why

Bios:

Dr Arjan Hura (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

William Wiley (guest)

William Wiley is a Board-Certified Ophthalmologist who has pioneered many eye procedures in the Northeast Ohio area. Dr. Wiley is the Medical Director of the Cleveland Eye Clinic. Dr. Wiley was one of the first in the area to offer his patients all-laser LASIK as well as laser-assisted refractive cataract surgery.

 

Summary:

In the last episode of ‘Peer2Peer: The Podcast’, OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3% series, the host, Dr Arjan Hura, shares a conversation with Dr. William Wiley from the Cleveland Eye Clinic about implementing OMIDRIA into clinical practice. The discussion dives into their early initial experiences with OMIDRIA through to today where it is employed in all of their cataract procedures.

 

Key Takeaways:

  • OMIDRIA has a noticeable impact when introduced as standard practice: Even as a surgeon in residency, Dr Hura’s experience was that the difference was dramatic: less complications after cataract surgeries, far less need for iris expansion devices, reduced pain following surgeries, and visually healthier eyes with less cell and improved visual acuity.
  • OMIDRIA provides constant infusion of dilation throughout a surgery and makes the lives of both patients and surgeons easier: Dr Wiley, though initially resistant to adopting OMIDRIA, quickly recognised the benefits including reduction of postoperative inflammation and pain.
  • OMIDRIA may reduce the need for risky painkillers: Dr Wiley has nearly eliminated the need for opioids such as fentanyl in postsurgical care by employing OMIDRIA during surgery.
  • OMIDRIA can lessen the need for post-operative drops: Dr Wiley shares that OMIDRIA, containing an intraoperative NSAID, has allowed his clinic to simplify their post-operative regimen to 1 drop per day.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

 

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

 

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

 

US-OM-2300033 07/23

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.

Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2023 Rayner Group, all rights reserved. US-OM-2200071v4 11/23